ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

NBIX Neurocrine Biosciences Inc

135,45
-0,81 (-0,59%)
15 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Neurocrine Biosciences Inc NBIX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,81 -0,59% 135,45 06:00:05
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
135,54 134,06 136,05 135,45 136,26
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
04.6.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.6.202414:01PRNUSNeurocrine Biosciences Presented CAHtalyst™ Phase 3..
03.6.202413:35PRNUSNeurocrine Biosciences Announces Publication of Primary..
03.6.202413:30PRNUSNeurocrine Biosciences Announces Publication of Primary..
30.5.202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.5.202422:53EDGAR2Form 144 - Report of proposed sale of securities
29.5.202422:01PRNUSNeurocrine Biosciences to Participate at Investor..
28.5.202422:14PRNUSNeurocrine Biosciences Announces CEO Succession Plan
28.5.202414:30PRNUSNeurocrine Biosciences to Present New Phase 3 CAHtalyst™..
24.5.202400:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.5.202400:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.5.202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.5.202400:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.5.202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.5.202400:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.5.202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.5.202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:01EDGAR2Form 8-K - Current report
21.5.202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202422:05PRNUSNeurocrine Biosciences Announces Publication of Phase 3..
17.5.202422:32EDGAR2Form 144 - Report of proposed sale of securities
17.5.202422:31EDGAR2Form 144 - Report of proposed sale of securities
17.5.202422:31EDGAR2Form 144 - Report of proposed sale of securities
16.5.202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.5.202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.5.202422:23EDGAR2Form 144 - Report of proposed sale of securities
14.5.202422:23EDGAR2Form 144 - Report of proposed sale of securities
14.5.202414:30PRNUSNeurocrine Biosciences Presented Baseline Data from the..
09.5.202415:45PRNUSNeurocrine Biosciences Presents CAHtalyst™ Adult Study..
09.5.202414:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
08.5.202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.5.202414:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
07.5.202422:15PRNUSNeurocrine Biosciences to Present at the BofA Securities..
07.5.202414:30PRNUSNeurocrine Biosciences to Present Phase 3 Baseline..
06.5.202414:30PRNUSNeurocrine Biosciences Supports Tardive Dyskinesia Awareness..
03.5.202419:15PRNUSNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study..
01.5.202413:00PRNUSNeurocrine Biosciences Reports First Quarter 2024 Financial..
30.4.202423:12PRNUSNeurocrine Biosciences Announces U.S. FDA Approval of..
24.4.202414:30PRNUSNeurocrine Biosciences Launches WHAT THE C@H?! Educational..
23.4.202413:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
16.4.202422:01GLOBESentia Medical Sciences and Neurocrine Biosciences Extend..
10.4.202422:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
03.4.202414:30PRNUSNeurocrine Biosciences Announces First-Patient Dosed in..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock